Angelo Labate1, Umberto Aguglia2, Giovanni Tripepi2, Laura Mumoli2, Edoardo Ferlazzo2, Rossella Baggetta2, Aldo Quattrone2, Antonio Gambardella1. 1. From the Institute of Neurology (A.L., U.A., L.M., E.F., A.Q., A.G.), University Magna Græcia, Catanzaro; Institute of Molecular Bioimaging and Physiology of the National Research Council (IBFM-CNR) (A.L., U.A., E.F., A.Q., A.G.), Viale Europa, Germaneto (CZ); and Institute of Clinical Physiology (G.T., R.B.), National Research Council (IFC-CNR), Research Unit, Reggio Calabria, Italy. labate@unicz.it a.gambardella@unicz.it. 2. From the Institute of Neurology (A.L., U.A., L.M., E.F., A.Q., A.G.), University Magna Græcia, Catanzaro; Institute of Molecular Bioimaging and Physiology of the National Research Council (IBFM-CNR) (A.L., U.A., E.F., A.Q., A.G.), Viale Europa, Germaneto (CZ); and Institute of Clinical Physiology (G.T., R.B.), National Research Council (IFC-CNR), Research Unit, Reggio Calabria, Italy.
Abstract
OBJECTIVE: To identify clinical and imaging features at presentation that might predict long-term outcome in patients with mild mesial temporal lobe epilepsy (mMTLE), which is defined by at least 24 seizure-free months with or without antiepileptic medication. METHODS: In the setting of a prospective, population-based, longitudinal cohort study, we followed up 101 patients, all with mMTLE at enrolment. By protocol, patients underwent clinical evaluation every 3-12 months. Independent t test, Mann-Whitney test, or χ(2) test was used for comparing 2 groups. The incidence rate of refractory MTLE (rMTLE) was expressed as number of cases every 100 person-years. RESULTS: After a mean follow-up of 12.2 ± 3.7 years, 16 patients dropped out and 85/101 (mean age 46.5 ± 13.3 years) were available for the present analysis. Of these, 64/85 (75%) patients remained seizure-free and 21/85 (25%) became refractory (rMTLE), the latter corresponding to 2.0 cases per 100 persons per year. Patients with rMTLE showed a longer duration of epilepsy (p < 0.001), earlier age at epilepsy onset (p = 0.006), more frequent febrile convulsions (p = 0.02), and hippocampal sclerosis (HS) at MRI (p = 0.004) as compared to those with mMTLE. CONCLUSIONS: mMTLE is a syndrome representing the mildest form of the wide spectrum of MTLE. Earlier age at onset, history of febrile convulsions, longer duration of epilepsy, and the presence of HS on MRI predict a worse outcome.
OBJECTIVE: To identify clinical and imaging features at presentation that might predict long-term outcome in patients with mild mesial temporal lobe epilepsy (mMTLE), which is defined by at least 24 seizure-free months with or without antiepileptic medication. METHODS: In the setting of a prospective, population-based, longitudinal cohort study, we followed up 101 patients, all with mMTLE at enrolment. By protocol, patients underwent clinical evaluation every 3-12 months. Independent t test, Mann-Whitney test, or χ(2) test was used for comparing 2 groups. The incidence rate of refractory MTLE (rMTLE) was expressed as number of cases every 100 person-years. RESULTS: After a mean follow-up of 12.2 ± 3.7 years, 16 patients dropped out and 85/101 (mean age 46.5 ± 13.3 years) were available for the present analysis. Of these, 64/85 (75%) patients remained seizure-free and 21/85 (25%) became refractory (rMTLE), the latter corresponding to 2.0 cases per 100 persons per year. Patients with rMTLE showed a longer duration of epilepsy (p < 0.001), earlier age at epilepsy onset (p = 0.006), more frequent febrile convulsions (p = 0.02), and hippocampal sclerosis (HS) at MRI (p = 0.004) as compared to those with mMTLE. CONCLUSIONS: mMTLE is a syndrome representing the mildest form of the wide spectrum of MTLE. Earlier age at onset, history of febrile convulsions, longer duration of epilepsy, and the presence of HS on MRI predict a worse outcome.
Authors: Graham R Huesmann; Hillary Schwarb; Daniel R Smith; Ryan T Pohlig; Aaron T Anderson; Matthew D J McGarry; Keith D Paulsen; Tracey Mencio Wszalek; Bradley P Sutton; Curtis L Johnson Journal: Neuroimage Clin Date: 2020-06-16 Impact factor: 4.881
Authors: David Pitskhelauri; Elina Kudieva; Maria Kamenetskaya; Antonina Kozlova; Pavel Vlasov; Baiyr Dombaanai; Natalia Eliseeva; Lyudmila Shishkina; Alexander Sanikidze; Evgeniy Shults; Dmitriy Moshev; Igor Pronin; Armen Melikyan Journal: Surg Neurol Int Date: 2021-07-27
Authors: Sanjay M Sisodiya; Christopher D Whelan; Sean N Hatton; Khoa Huynh; Andre Altmann; Mina Ryten; Annamaria Vezzani; Maria Eugenia Caligiuri; Angelo Labate; Antonio Gambardella; Victoria Ives-Deliperi; Stefano Meletti; Brent C Munsell; Leonardo Bonilha; Manuela Tondelli; Michael Rebsamen; Christian Rummel; Anna Elisabetta Vaudano; Roland Wiest; Akshara R Balachandra; Núria Bargalló; Emanuele Bartolini; Andrea Bernasconi; Neda Bernasconi; Boris Bernhardt; Benoit Caldairou; Sarah J A Carr; Gianpiero L Cavalleri; Fernando Cendes; Luis Concha; Patricia M Desmond; Martin Domin; John S Duncan; Niels K Focke; Renzo Guerrini; Khalid Hamandi; Graeme D Jackson; Neda Jahanshad; Reetta Kälviäinen; Simon S Keller; Peter Kochunov; Magdalena A Kowalczyk; Barbara A K Kreilkamp; Patrick Kwan; Sara Lariviere; Matteo Lenge; Seymour M Lopez; Pascal Martin; Mario Mascalchi; José C V Moreira; Marcia E Morita-Sherman; Heath R Pardoe; Jose C Pariente; Kotikalapudi Raviteja; Cristiane S Rocha; Raúl Rodríguez-Cruces; Margitta Seeck; Mira K H G Semmelroch; Benjamin Sinclair; Hamid Soltanian-Zadeh; Dan J Stein; Pasquale Striano; Peter N Taylor; Rhys H Thomas; Sophia I Thomopoulos; Dennis Velakoulis; Lucy Vivash; Bernd Weber; Clarissa Lin Yasuda; Junsong Zhang; Paul M Thompson; Carrie R McDonald Journal: Hum Brain Mapp Date: 2020-05-29 Impact factor: 5.038